Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trastuzumab duocarmazine by Byondis for Metastatic Breast Cancer: Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...
Trastuzumab duocarmazine by Byondis for Ovarian Cancer: Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Trastuzumab duocarmazine by Byondis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase II for Human Epidermal Growth Factor Receptor 2...